Royalty Report: Drugs, Delivery, Pharmaceuticals – Collection: 27852

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Delivery
  • Pharmaceuticals
  • Cannabis
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27852

License Grant
The Licensee announced that it has entered into a non-binding Letter of Intent to license the Canadian Licensor's proprietary RapidMistâ„¢ drug delivery technologies for the delivery of medicinal and recreational cannabis derived products into the bloodstream through the buccal membrane.
License Property
The RapidMistâ„¢ drug delivery platform administers medications directly into the mouth as a metered dose spray for rapid absorption by the buccal mucosa.
Field of Use
The Licensee is a provider of consulting and advisory services to licensed medical and recreational marijuana operators and retail dispensaries within the United States.

Licensor's most advanced product in development using RapidMistâ„¢ is Generex Oral-lynâ„¢, an insulin spray product for the treatment of diabetes mellitus.

IPSCIO Record ID: 305318

License Grant
The agreement provides for the Licensor’s grant of a non-exclusive right and sub-license to use certain Licensor technology and intellectual property to develop and commercialize products for sale in Europe, the Middle East, and Africa.

The term of the agreement ends the earlier of (i) July 15, 2020 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $1,000,000 for the previous year.

License Property
The technology is for eluting patches.

Licensor has acquired an exclusive, worldwide license for an eluting transmucosal patch platform (ETP) for non-invasive drug delivery in the cannabis field.

Licensor is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems.

Field of Use
The Technology is centered around an eluting patch platform (“ETP”), which is a bio adhesive, transmucosal orally dissolving thin film system. The platform allows for actives loaded onto the ETP to be absorbed by the buccal mucosa into the body.

The license is for transmucosal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids.

Licensor’s oral patch has been shown in clinical studies to be a safe, accurate and effective way to deliver lower doses of pharmaceutical actives, while achieving high levels of bioavailability.
The OralTabs product contains 21mg of full spectrum CBD in each tab and is available in 5 and 30 pack boxes in a wild mint berry flavor with additional packet sizes, formulations and flavors planned for later on in the year.

With concern growing over vaping and the numerous incidents now being reported, Licensee’s oral patch, provides a safe alternative delivery platform that can be utilised to deliver cannabinoids directly into the body without the harmful side effects of smoking or vaping, and with quicker onset and greater bioavailability than ingestibles.  Licensee is dedicated to the production, research, cultivation, processing and distribution of medicinal cannabis oil to pharmaceutical companies worldwide.

IPSCIO Record ID: 4186

License Grant
The Company will grant an exclusive, worldwide License to its buccal drug delivery technologies to the Licensee for use with certain of Licensee proprietary technologies.
License Property
The Company will fund direct expenditures incurred in the collaborative research and development in accord with a budget to be agreed upon, up to a maximum of $5,000,000 over a period of three years.
Field of Use
The parties will collaborate in the research and development of certain of the Licensee's proprietary technologies for application in the treatment of diabetes.  

The Licensee will bear all costs associated with such use, but the Company will retain ownership of any improvements to its buccal drug delivery technologies.

IPSCIO Record ID: 328330

License Grant
Licensor hereby grants to Licensee and Licensee accepts, a non-transferable, sublicenseable, royalty-bearing, exclusive right and license under the Licensed Technology to Exploit the Licensed Product in the Territory, to the full end of the Term for which the Licensed Technology is licensed, unless sooner terminated as herein after provided.
License Property
Technology shall mean with respect to lingual sprays for the metered delivery of pharmaceutical products to humans.

United States Patent No. 6,676,931 B2 – Buccal, polar and non-polar spray or capsule

Licensed Technology shall mean the Licensor Patents, the Licensor Know-How and the Drug Master File, collectively, but only with respect to the Exploitation of the Licensed Product.

Licensed Product shall mean any dosage of pharmaceutical composition or preparation in finished form labeled and packaged for sale by prescription, over-the-counter or any other method only for human application that contains, as the sole ingredient, the Designated Compound delivered by means of the Licensed Process.

Field of Use
Field of use is for the metered delivery of pharmaceutical products to humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.